OConnell Daniel Joseph's Form 4 filing
Acumen Pharmaceuticals, Inc. (ABOS) · filed Jan 19, 2024
- Accession no.
- 0001576885-24-000029
- Filed
- Jan 19, 2024
- Trade date
- Jan 19, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $52.7K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OConnell Daniel JosephCIK 0001865136 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 19, 2024 | Common Stock | SSaleDisposed | −15,200 | $3.47F2 | −$52,744 | 502,485 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.3950 to $3.6500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.